| cardiac gene therapy companies: Cardiac Regeneration Masaki Ieda, Wolfram-Hubertus Zimmermann, 2017-10-27 This Volume of the series Cardiac and Vascular Biology offers a comprehensive and exciting, state-of-the-art work on the current options and potentials of cardiac regeneration and repair. Several techniques and approaches have been developed for heart failure repair: direct injection of cells, programming of scar tissue into functional myocardium, and tissue-engineered heart muscle support. The book introduces the rationale for these different approaches in cell-based heart regeneration and discusses the most important considerations for clinical translation. Expert authors discuss when, why, and how heart muscle can be salvaged. The book represents a valuable resource for stem cell researchers, cardiologists, bioengineers, and biomedical scientists studying cardiac function and regeneration. |
| cardiac gene therapy companies: Genetic Cardiomyopathies Gianfranco Sinagra, Fulvio Camerini, Luisa Mestroni, 2012-12-09 In the last decade, genetics has been emerging as a primary issue in the diagnosis and management of cardiomyopathies. This book is intended to be a state-of-the-art monograph on these diseases, describing their genetic causes, defining the molecular basis and presenting extensive descriptions of genotype–phenotype correlations. Other chapters are focused on the role of clinical observation, on ECG and echocardiography. With its highlight on the most recent discoveries in the field of molecular genetics as well as on the correct clinical approach to patients with heart muscle disease, the book is aimed at physicians and clinical cardiologists with a particular interest in myocardial diseases and in their genetic causes. |
| cardiac gene therapy companies: Cardiac Gene Therapy Kiyotake Ishikawa, 2016-12-02 This detailed book provides methodological information on cardiac gene delivery, from classic to state-of-the-art technologies and techniques. Efficient, cardiac-specific, and safe vectors, as well as refined vector delivery methods, are key for successful cardiac gene transfer and eventually for improving patients’ outcomes. Newer vectors and more efficient vector delivery methods have the potential to dramatically improve gene transduction efficacy, while novel gene manipulation techniques enforce the therapeutic power and broaden disease targets. Written for the highly successful Methods in Molecular Biology series, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Authoritative and practical, Cardiac Gene Therapy: Methods and Protocols serves as a valuable tool for molecular biologists and physiologists in the cardiology field conducting cardiac gene transfer research, which will ultimately lead to further advancements in the vital field. |
| cardiac gene therapy companies: A Special Report on Gene Therapy K. K. Jain, Kewal K. Jain, 2000-04-14 This special report on Gene Therapy Companies by K.K. Jain provides an up-to-date overview of the gene therapy industry. It contains a wealth of very practical information on 105 companies. For each company, information is available on the people to contact, their contact details, a corporate history, the company's technologies and products, financial data, patents held, products in clinical trials, collaborations with other companies and selected publications from the company's scientists. Almost 200 companies were initially considered for inclusion but just over 100 companies were finally selected as they fulfilled the necessary criteria to be classified as a 'Gene Therapy Company,', defined broadly to include cell therapy companies. Not all of the companies devote their activity exclusively to gene therapy but they have sufficient relevance to be included. As part of this project, new companies were discovered that have not been reported in other publications or on the internet. Dr. Jain has spared no effort to ensure that the information is up-to-date and accurate at the time of publishing. In most instances, the information was reviewed by the companies to correct any outdated information or to add any complementary or recent information. In addition to the detailed descriptions of each company, the data is also presented in summary tabular form so that at a glance the reader can identify collaborations within the gene therapy industry, or determine which companies are pursuing strategies involving viral, non-viral or other approaches to gene therapy, and which diseases are being targetted. Given that much of the gene therapy research and development is currently being carried out within the industrial sector, it is important for scientists, managers and investors to have the relevant information at their fingertips. This special report provides that information in one accurate, easy to consult and up-to-date source. |
| cardiac gene therapy companies: Cardiac Diseases David C. Gaze, Aleksandar Kibel, 2021-07-28 This is the latest book in a series of cardiovascular-related texts from IntechOpen Publishing. The present volume considers general aspects of cardiac disease and is divided into three distinct sections covering cardiac risk, cardiorenal pathology, and novel interventional surgical techniques. The chapters offer insight into the current state of the art with respect to the risks of developing cardiovascular diseases, maintenance of patent vascular access in patients with the cardiorenal syndrome, and a plethora of novel interventional technologies all aimed at salvaging damaged tissue and improving prognosis and reducing mortality. This volume of 18 chapters is intended for general medical and biomedical students at both undergraduate and postgraduate level. It also offers insightful updates on recent advances in the understanding of the pathophysiology of cardiac diseases and the new techniques added to the medical armamentarium to improve the outcomes and prevent mortality and would be of interest to those working in academia and healthcare science. |
| cardiac gene therapy companies: Accelerating the Development of Biomarkers for Drug Safety Institute of Medicine, Board on Health Sciences Policy, Forum on Drug Discovery, Development, and Translation, 2009-07-20 Biomarkers can be defined as indicators of any biologic state, and they are central to the future of medicine. As the cost of developing drugs has risen in recent years, reducing the number of new drugs approved for use, biomarker development may be a way to cut costs, enhance safety, and provide a more focused and rational pathway to drug development. On October 24, 2008, the IOM's Forum on Drug Discovery, Development, and Translation held Assessing and Accelerating Development of Biomarkers for Drug Safety, a one-day workshop, summarized in this volume, on the value of biomarkers in helping to determine drug safety during development. |
| cardiac gene therapy companies: Stem Cell and Gene Therapy for Cardiovascular Disease Emerson c. Perin, Leslie W. Miller, Doris Taylor, James T. Willerson, 2015-08-21 Stem Cell and Gene Therapy for Cardiovascular Disease is a state-of-the-art reference that combines, in one place, the breadth and depth of information available on the topic. As stem cell and gene therapies are the most cutting-edge therapies currently available for patients with heart failure, each section of the book provides information on medical trials from contributors and specialists from around the world, including not only what has been completed, but also what is planned for future research and trials. Cardiology researchers, basic science clinicians, fellows, residents, students, and industry professionals will find this book an invaluable resource for further study on the topic. - Provides information on stem and gene therapy medical trials from contributors and specialists around the world, including not only what has been completed, but also what is planned for future research and trials - Presents topics that can be applied to allogeneic cells, mesenchymal cells, gene therapy, cardiomyoctyes, iPS cells, MAPC's, and organogenesis - Covers the three areas with the greatest clinical trials to date: chronic limb ischemia, chronic angina, and acute MI - Covers the prevailing opinions on how to harness the body's natural repair mechanisms - Ideal resource for cardiology researchers, basic science clinicians, fellows, residents, students, and industry professionals |
| cardiac gene therapy companies: Sendai Virus Vector Yoshiyuki Nagai, 2014-01-31 Sendai virus (SeV) is not just a mouse pathogen but is evolving into a cutting-edge component of biotechnology. SeV reverse genetics originating from a pure academic need to settle long-held questions in the biology and pathogenicity of nonsegmented negative strand RNA viruses (Mononegavirales) is about to bear the impressive fruit of multipurpose cytoplasmic (non-integrating) RNA vectors. This book brings together in one source the SeV biology revealed by conventional approaches and reverse genetics, the methods to construct the first-generation SeV vector and to generate safer versions, and the applications in medical settings that have left or are about to leave the laboratory bench. The applications, which already are diverse and have high medical impact, include use as vaccine vectors against AIDS and respiratory virus infections, creation of BioKnife to resect malignant tumors, induction of “footprint (transgene) free” pluripotent stem cells, and gene therapy for peripheral arterial disease. These achievements—which are just a few of many examples—were attainable only after rigorously incorporating the rich knowledge of SeV biology that has accumulated during the several decades since the discovery of the virus. Application of SeV vector is certain to expand greatly because of its extremely high performance in transgene expression and its remarkable target cell breadth. |
| cardiac gene therapy companies: Applications of Biotechnology in Cardiovascular Therapeutics Kewal K. Jain, 2011-07-25 For physicians, surgeons, and scientists working on cardiovascular disorders, Applications of Biotechnology in Cardiovascular Therapeutics serves as an invaluable reference by collecting the essential writings of Dr. Kewal K. Jain on the topics of biotechnology as they relate to cardiovascular disease. This thorough volume includes such subjects as biotechnology and therapeutic delivery to the cardiovascular system, cell-selective targeted drug delivery, cell and gene therapies, including antisense and RNA interference, cutting-edge gene therapy approaches, as well as personalized cardiology as a way of integrating new technologies into the selection of the best possible treatment for an individual patient. Selected references from recent literature are collected for each chapter, and the text is supplemented by a variety of useful tables and figures. Comprehensive and up-to-date, Applications of Biotechnology in Cardiovascular Therapeutics will be tremendously useful for those working in life sciences and the pharmaceutical sciences, and the inclusion of some basics of cardiovascular diseases will greatly benefit nonmedical readers as well. |
| cardiac gene therapy companies: Ageless Nation Michael G. Zey, 2017-07-05 In this intriguing volume, futurist and author Michael G. Zey imagines a time in which technology has stretched human life spans to four hundred years or more. Genetic engineering, cloning, and stem-cell technology will eradicate diseases and allow for nanoscopic repair and maintenance of the body. Smart drugs and caloric restriction programs will largely stop aging and ensure healthy bodies and sharp minds indefinitely.Grounding his speculation in contemporary scientific research, Zey's optimistic vision sees retirement replaced by hiatuses between careers, and leisure time spent in multi-generational homes. Key players in the debate include supporters like Cambridge University scientist Aubrey de Grey, who envisions five-thousand-year life spans, and the radical futurist author Ray Kurzweil, who foresees the merging of humans and computers. Organizations such as the Coalition to Extend Life lobby the government for immortality research funding and find opposition in the President's Council on Bioethics and deep ecologists advocating zero-population growth.Criticizing current environmental trends as anti-progress and anti-human, Zey's own solutions include controversial measures like human control of weather, colonization of outer space, and genetically modifying food. He concludes that the eventuality of a modern Fountain of Youth is closer than we think. Zey's predictions about the future are thoughtful and fascinating. |
| cardiac gene therapy companies: Cardioprotection Derek Hausenloy, Derek Yellon, 2009-08-20 Coronary heart disease (CHD) is the leading cause of death worldwide. Cardioprotection refers to the prevention of CHD and the clinical improvement in patients suffering from cardiovascular problems. |
| cardiac gene therapy companies: Adenoviral Vectors for Gene Therapy David T. Curiel, 2016-03-10 Adenoviral Vectors for Gene Therapy, Second Edition provides detailed, comprehensive coverage of the gene delivery vehicles that are based on the adenovirus that is emerging as an important tool in gene therapy. These exciting new therapeutic agents have great potential for the treatment of disease, making gene therapy a fast-growing field for research. This book presents topics ranging from the basic biology of adenoviruses, through the construction and purification of adenoviral vectors, cutting-edge vectorology, and the use of adenoviral vectors in preclinical animal models, with final consideration of the regulatory issues surrounding human clinical gene therapy trials. This broad scope of information provides a solid overview of the field, allowing the reader to gain a complete understanding of the development and use of adenoviral vectors. - Provides complete coverage of the basic biology of adenoviruses, as well as their construction, propagation, and purification of adenoviral vectors - Introduces common strategies for the development of adenoviral vectors, along with cutting-edge methods for their improvement - Demonstrates noninvasive imaging of adenovirus-mediated gene transfer - Discusses utility of adenoviral vectors in animal disease models - Considers Federal Drug Administration regulations for human clinical trials |
| cardiac gene therapy companies: Directory of Biotechnology Companies , 2000 |
| cardiac gene therapy companies: The SAGE Handbook of Healthcare Decision Resources Inc, 2008-05-22 With escalating healthcare costs, changes to the regulatory control on pharmaceutical industries and the inevitable adjustments made in policies and investment in healthcare there is enormous interest in the commercial as well as the scientific aspects of today′s healthcare industry. The SAGE Handbook of Healthcare provides an authoritative analysis of the current (and anticipated) developments in the global healthcare industries. Providing a unique perspective that interfaces between the science and business aspects, it combines information on the latest scientific developments with applied, commercial business data from the global marketplace. The Handbook focuses on the aspects of paramount importance in the healthcare sector: - Pharmacoeconomics - Pharmacogenomics - Therapeutics - Diagnostics Areas covered include: - The role of nanotechnology, genomics and cell therapy in medicine - Diagnostics; Biomarkers and technological advances - Case studies in oncology and cardiovascular and CNS therapeutics |
| cardiac gene therapy companies: A Guide to Human Gene Therapy Roland W. Herzog, Sergei Zolotukhin, 2010 1. Non-viral gene therapy / Sean M. Sullivan -- 2. Adenoviral vectors / Stuart A. Nicklin and Andrew H. Baker -- 3. Retroviral vectors and integration analysis / Cynthia C. Bartholomae [und weitere] -- 4. Lentiviral vectors / Janka Matrai, Marinee K.L. Chuah and Thierry VandenDriessche -- 5. Herpes simplex virus vectors / William F. Goins [und weitere] -- 6. Adeno-Associated Viral (AAV) vectors / Nicholas Muzyczka -- 7. Regulatory RNA in gene therapy / Alfred. S. Lewin -- 8. DNA integrating vectors (Transposon, Integrase) / Lauren E. Woodard and Michele P. Calos -- 9. Homologous recombination and targeted gene modification for gene therapy / Matthew Porteus -- 10. Gene switches for pre-clinical studies in gene therapy / Caroline Le Guiner [und weitere] -- 11. Gene therapy for central nervous system disorders / Deborah Young and Patricia A. Lawlor -- 12. Gene therapy of hemoglobinopathies / Angela E. Rivers and Arun Srivastava -- 13. Gene therapy for primary immunodeficiencies / Aisha Sauer, Barbara Cassani and Alessandro Aiuti -- 14. Gene therapy for hemophilia / David Markusic, Babak Moghimi and Roland Herzog -- 15. Gene therapy for obesity and diabetes / Sergei Zolotukhin and Clive H. Wasserfall -- 16. Gene therapy for Duchenne muscular dystrophy / Takashi Okada and Shin'ichi Takeda -- 17. Cancer gene therapy / Kirsten A.K. Weigel-Van Aken -- 18. Gene therapy for autoimmune disorders / Daniel F. Gaddy, Melanie A. Ruffner and Paul D. Robbins -- 19. Gene therapy for inherited metabolic storage diseases / Cathryn Mah -- 20. Retinal diseases / Shannon E. Boye, Sanford L. Boye and William W. Hauswirth -- 21. A brief guide to gene therapy treatments for pulmonary diseases / Ashley T. Martino, Christian Mueller and Terence R. Flotte -- 22. Cardiovascular disease / Darin J. Falk, Cathryn S. Mah and Barry J. Byrne |
| cardiac gene therapy companies: Data-Driven Innovation Big Data for Growth and Well-Being OECD, 2015-10-06 This report improves the evidence base on the role of Data Driven Innovation for promoting growth and well-being, and provide policy guidance on how to maximise the benefits of DDI and mitigate the associated economic and societal risks. |
| cardiac gene therapy companies: Encyclopedia of Heart Diseases M. Gabriel Khan, 2005-12-14 The Encyclopedia of Heart Diseases is an accurate and reliable source of in-depth information on the diseases that kill more than 12 million individuals worldwide each year. In fact, cardiovascular diseases are more prevalent than the combined incidence of all forms of cancer, diabetes, asthma and leukemia. In one volume, this Encylopedia thoroughly covers these ailments and also includes in-depth analysis of less common and rare heart conditions to round out the volume's scope. Researchers, clinicians, and students alike will all find this resource an invaluable tool for quick reference before approaching the primary literature.* Coverage of more than 200 topics, including: applied pharmacology of current and experimental cardiac drugs, gene therapy, MRI, electron-beam CT, PET scan put in perspective, cardiac tests costs and justification, and new frontiers in cardiovascular research* More than 150 helpful figures and illustrations!* Dr. Khan is a well-published and respected expert in heart and heart diseases |
| cardiac gene therapy companies: Heart Failure: A Companion to Braunwald's Heart Disease E-Book G. Michael Felker, Douglas L. Mann, 2019-02-06 Up-to-date, authoritative and comprehensive, Heart Failure, 4th Edition, provides the clinically relevant information you need to effectively manage and treat patients with this complex cardiovascular problem. This fully revised companion to Braunwald's Heart Disease helps you make the most of new drug therapies such as angiotensin receptor neprilysin inhibitors (ARNIs), recently improved implantable devices, and innovative patient management strategies. Led by internationally recognized heart failure experts Dr. G. Michael Felker and Dr. Douglas Mann, this outstanding reference gives health care providers the knowledge to improve clinical outcomes in heart failure patients. - Focuses on a clinical approach to treating heart failure, resulting from a broad variety of cardiovascular problems. - Covers the most recent guidelines and protocols, including significant new updates to ACC, AHA, and HFSA guidelines. - Covers key topics such as biomarkers and precision medicine in heart failure and new data on angiotensin receptor neprilysin inhibitors (ARNIs). - Contains four new chapters: Natriuretic Peptides in Heart Failure; Amyloidosis as a Cause of Heart Failure; HIV and Heart Failure; and Neuromodulation in Heart Failure. - Covers the pathophysiological basis for the development and progression of heart failure. - Serves as a definitive resource to prepare for the ABIM's Heart Failure board exam. - 2016 British Medical Association Award: First Prize, Cardiology (3rd Edition). |
| cardiac gene therapy companies: Molecular Basis of Cardiovascular Disease Kenneth R. Chien, 2004 The 2nd Edition of this heralded companion to Braunwald's Heart Disease explores the molecular mechanisms of cardiology and the scientific advances that are changing the practice of cardiology today. International experts discuss the role of genetics in cardiovascular disease the molecular basis of ischemic disease, thrombosis and hypertension genetic mapping approaches to inherited disorders biologically targeted agents for hypertension and heart failure and much more. Abundant figures and tables illustrate key concepts. Addresses most common cardiovascular problems from a molecular standpoint. Explores developing treatments for cardiovascular problems based on genetics. Provides references to Braunwald's Heart Disease, 6th Edition Examines today's cutting edge advances in molecular cardiology and the future of gene therapy, Examines the implications of cellular cholesterol metabolism in health and disease. . Delivers up-to-date information on understanding the origin of inherited disease. |
| cardiac gene therapy companies: Midkine: From Embryogenesis to Pathogenesis and Therapy Mine Ergüven, Takashi Muramatsu, Ayhan Bilir, 2012-06-12 Carl Edward Sagan’s (1934-1996) one of the famous quotation was “Who are we? We find that we live on an insignificant planet of a humdrum star lost in a galaxy tucked away in some forgotten corner of a universe in which there are far more galaxies than people.“ From past to date, well-known molecules, enzymes, proteins, lipids and carbohydrates are studied in the pathogenesis of several diseases both as a diagnostic/prognostic biomarker and therapeutic agent. The underlying mechanism of unexplained diseases and failure of therapies are frequently studied with well-known biomarkers, but remain unclear in many cases. As Dr. Sagan said other keys are still waiting to be known in some forgotten corner of a body universe, we find strength to propose that one of them can be the growth factor with cytokine activity named “Midkine” This book summarizes the extensive up-to-date literature overeview with the lastest work of experts about midkine in a detailed format that conveys its role as both a pathologic factor and therapeutic agent. |
| cardiac gene therapy companies: Emerging Technologies for Heart Diseases Udi Nussinovitch, 2020-08-19 The increasing pace of advances in cardiology throughout the last few decades has fundamentally altered the natural course of heart patients. In the last few years, available therapies have been revolutionized completely by new transcatheter therapeutic approaches, novel ventricular assist devices, and new drugs. Also, molecular biology and genetics have a rapidly growing impact on cardiovascular diseases, enabling the field of regenerative medicine to become increasingly closer to routine clinical implementation. Emerging Technologies for Heart Diseases was conceived to cover the recent extensive literature on current and novel therapeutic options for cardiac patients. The first volume is dedicated to heart failure and valvular disorders, and the second covers myocardial ischemia and arrhythmias. The clinical topic is addressed in several chapters divided according to the therapeutic approach (mechanical or electrical device-based, or cell and gene-based). Each of the 46 chapters focuses on clinically available solutions, new therapies currently under evaluation in clinical trials, promising preclinical technologies, and emerging concepts and innovations that have not yet been tested in a preclinical model. Also, the book discusses future challenges and opportunities for clinical implementation. Lessons learned from abandoned experimental practices are also covered, giving the readers the widest possible perspective of current therapeutic dilemmas. Overall, this textbook was designed for physicians who want to stay up-to-date with current therapies and those of the future, for biomedical companies, and for those who wish to broaden their knowledge of new cardiovascular therapeutic options. - Provides a comprehensive review of the latest therapeutic developments for heart failure, valvular disorders, myocardial ischemia and arrhythmias, and their clinical implications - Written by both specialists in the field and established researchers, it delivers a review of emerging medical technologies and presents insight into their therapeutic promise - Chapters are arranged according to disease pathogeneses and relevance and include coverage of the mechanical, electrophysiological, and biological approaches for the management of patients with myocardial ischemia and arrhythmias |
| cardiac gene therapy companies: Gene Therapy Kenneth W. Culver, 1996 |
| cardiac gene therapy companies: The Artificial Heart Institute of Medicine, Division of Health Care Services, Committee to Evaluate the Artificial Heart Program of the National Heart, Lung, and Blood Institute, 1991-02-01 A significant medical event is expected in 1992: the first human use of a fully implantable, long-term cardiac assist device. This timely volume reviews the artificial heart program-and in particular, the National Institutes of Health's major investment-raising important questions. The volume includes: Consideration of the artificial heart versus heart transplantation and other approaches to treating end-stage heart disease, keeping in mind the different outcomes and costs of these treatments. A look at human issues, including the number of people who may require the artificial heart, patient quality of life, and other ethical and societal questions. Examination of how this technology's use can be targeted most appropriately. Attention to achieving access to this technology for all those who can benefit from it. The committee also offers three mechanisms to aid in allocating research and development funds. |
| cardiac gene therapy companies: Congestive Heart Failure Jeffrey D. Hosenpud, Barry H. Greenberg, 2007 Written by recognized leaders in the field, Congestive Heart Failure, Third Edition is a comprehensive, state-of-the-art reference on all basic and clinical aspects of heart failure. Coverage includes an entire section on pharmacologic therapy and a twenty-chapter section on clinical approaches to acute and chronic heart failure. This edition has new chapters on impact and treatment of comorbidities, prevention of sudden cardiac death, rationale for use of anticoagulants, ultrafiltration, use of mechanical devices, and gene and cell therapy. Readers will find up-to-date information on genetics, surgical therapies, ventricular synchronization, defibrillator therapy, mechanical approaches to atrial fibrillation, left ventricular assist devices, ventricular support and ventricular remodeling surgery, and myocardial regeneration/cell transplantation. |
| cardiac gene therapy companies: Cardiovascular Genetics for Clinicians P.A.F.M. Doevendans, A.A.M. de Wilde, 2012-12-06 All physicians practicing medicine encounter patients suffering from cardiovascular disease. This book has been outlined in such a way that vascular surgeons, general internists, neurologists and cardiologists should be able to use it. The book covers the complete scope of cardiac diseases in addition to chapters on hypertension and atherosclerosis. In many patients there is a family history of cerebrovascular accidents, myocardial infarction or peripheral arterial disease. Also in patients reporting collaps, palpitations and arrhythmias the family is crucial and can provide clues to a genetic cause of the disease. This book is published to guide physicians in the process of determining whether a genetic component is likely to be present. Furthermore, information is provided what the possibilities and limitations of DNA diagnostic techniques are. Finally, the importance of newly identified categories of potential patients, i. e. gene carriers without symptoms or any inducible sign of disease, is highlighted. For some patients a genetic diagnosis is essential to determine appropriate therapy and for counseling? In some other diseases DNA diagnostic tools are available but the relevant for the patients may be less clear. In other families the search for a disease causing gene is ongoing and the possibilities to find genes and to unravel the pathophysiology of the disease is limited by the lack of patients. To give insight into the current state of genetic diagnostics, the authors have classified the cardiovascular diseases. |
| cardiac gene therapy companies: Muscle Gene Therapy Dongsheng Duan, Jerry R. Mendell, 2019-03-30 About 7 million people worldwide are suffering from various inherited neuromuscular diseases. Gene therapy brings the hope of treating these diseases at their genetic roots. Muscle Gene Therapy is the only book dedicated to this topic. The first edition was published in 2010 when the field was just about to enter its prime time. The progress made since then has been unprecedented. The number of diseases that have been targeted by gene therapy has increased tremendously. The gene therapy toolbox is expanded greatly with many creative novel strategies (such as genome editing and therapy with disease-modifying genes). Most importantly, clinical benefits have begun to emerge in human patients. To reflect rapid advances in the field, we have compiled the second edition of Muscle Gene Therapy with contributions from experts that have conducted gene therapy studies either in animal models and/or in human patients. The new edition offers a much needed, up-to-date overview and perspective on the foundation and current status of neuromuscular disease gene therapy. It provides a framework to the development and regulatory approval of muscle gene therapy drugs in the upcoming years. This book is a must-have for anyone who is interested in neuromuscular disease gene therapy including those in the research arena (established investigators and trainees in the fields of clinical practice, veterinary medicine and basic biomedical sciences), funding and regulatory agencies, and patient community. |
| cardiac gene therapy companies: Modern Biopharmaceuticals, 4 Volume Set Jörg Knäblein, 2005-10-28 The biopharmaceutical market has come along way since 1982 when the first biopharmaceutical product, recombinant human insulin, was launched. Over 120 such products are currently being marketed around the world including nine blockbuster drugs. The global market for biopharmaceuticals, which is currently valued at US$41 billion, has been growing at an impressive compound annual growth rate of 21% over the previous five years. With over one third of all pipe-line products in active development are biopharmaceuticals, this segment is set to continue outperforming the total pharmaceutical market and could easily reach US$100 billion by the end of this decade. |
| cardiac gene therapy companies: Genome Editing in Cardiovascular and Metabolic Diseases Junjie Xiao, 2022-12-01 This book provides the latest research progress on genome editing in cardiovascular and metabolic diseases and includes bioinformatics research methodology of genome editing. Genome editing is a genetic engineering technique precisely modified specific target genes of organism genome, which has been applied to basic theoretical research and production applications from plants and animals to gene therapy of human beings. Cardiovascular and metabolic diseases have become major factors affecting human health worldwide. This book contains information about bioinformatics, genome editing in cardiovascular diseases, genome editing in metabolic diseases and therapeutic effects. It will be useful for biologist, cardiologist, cardiovascular surgeons, endocrinologist, internists, nurses, undergraduate and graduate students in medicine and cell biology and others interested in cardiovascular and metabolic medicine. |
| cardiac gene therapy companies: Principles of Safety Pharmacology Michael K. Pugsley, Michael J Curtis, 2015-06-19 This book illustrates, in a comprehensive manner, the most current areas of importance to Safety Pharmacology, a burgeoning unique pharmacological discipline with important ties to academia, industry and regulatory authorities. It provides readers with a definitive collection of topics containing essential information on the latest industry guidelines and overviews current and breakthrough topics in both functional and molecular pharmacology. An additional novelty of the book is that it constitutes academic, pharmaceutical and biotechnology perspectives for Safety Pharmacology issues. Each chapter is written by an expert in the area and includes not only a fundamental background regarding the topic but also detailed descriptions of currently accepted, validated models and methods as well as innovative methodologies used in drug discovery. |
| cardiac gene therapy companies: Prevalence of Uncontrolled Risk Factors for Cardiovascular Disease Cheryl D. Fryar, Te-Ching Chen, Xianfen Li, 2012 |
| cardiac gene therapy companies: Guidelines for Cardiac Rehabilitation and Secondary Prevention Programs American Association of Cardiovascular & Pulmonary Rehabilitation, 2004 This edition addresses the cost effectiveness of interventions that educate and motivate patients to assume personal responsibility for long-term disease prevention. |
| cardiac gene therapy companies: Intellectual Property Russell L. Parr, Gordon V. Smith, 2005-04-29 This book is designed to simplify the process of attaching a dollar amount to intangible assets, be it for licensing, mergers and acquisitions, loan collateral, or investment purposes. It provides practical tools for evaluating the investment aspects of licensing and joint venture decisions, and discusses the legal, tax, and accounting practices and procedures related to such arrangements; examines the business economics of strategies involving intellectual property licensing and joint ventures; and provides analytical models that can be used to determine reasonable royalty rates for licensing and for determining fair equity splits in joint venture arrangements. |
| cardiac gene therapy companies: Human Genome Editing National Academies of Sciences, Engineering, and Medicine, National Academy of Medicine, National Academy of Sciences, Committee on Human Gene Editing: Scientific, Medical, and Ethical Considerations, 2017-08-13 Genome editing is a powerful new tool for making precise alterations to an organism's genetic material. Recent scientific advances have made genome editing more efficient, precise, and flexible than ever before. These advances have spurred an explosion of interest from around the globe in the possible ways in which genome editing can improve human health. The speed at which these technologies are being developed and applied has led many policymakers and stakeholders to express concern about whether appropriate systems are in place to govern these technologies and how and when the public should be engaged in these decisions. Human Genome Editing considers important questions about the human application of genome editing including: balancing potential benefits with unintended risks, governing the use of genome editing, incorporating societal values into clinical applications and policy decisions, and respecting the inevitable differences across nations and cultures that will shape how and whether to use these new technologies. This report proposes criteria for heritable germline editing, provides conclusions on the crucial need for public education and engagement, and presents 7 general principles for the governance of human genome editing. |
| cardiac gene therapy companies: Mechanical Circulatory Support: A Companion to Braunwald's Heart Disease Ebook Robert L. Kormos, Leslie W. Miller, 2011-08-30 Mechanical Circulatory Support, by Drs. Robert L. Kormos and Leslie W. Miller, provides the clinically relevant information you need to effectively use this therapy to treat and manage end-stage cardiovascular disease. In this Companion to Braunwald’s Heart Disease, the world’s most prominent experts in mechanical circulatory support (MCS) cover basic science, device construction, clinical applications, socioeconomic implications, future directions, and more. Stay on top of hot topics - including innovative devices like continuous flow pumps, next-generation centrifugal pumps, and total artificial hearts; MCS for pediatric and congenital heart disease; cellular, molecular, genomic, and functional changes that occur in the failing heart in response to MCS; and Interagency Registry of Mechanically Assisted Circulatory Support (INTERMACS) as a tool to track and advance clinical practice. Tap into discussions of hot topics in mechanical circulatory support (MCS), including current types of devices and clinical settings for MCS; MCS for pediatric and congenital heart disease; myocardial recovery, regenerative therapy, bleeding and thrombosis with MCS; cellular, molecular, genomic, and functional changes that occur in the failing heart in response to MCS; and Interagency Registry of Mechanically Assisted Circulatory Support (INTERMACS) as a tool to track and advance clinical practice. Get a complete picture of the role of mechanical circulatory support in treatment through coverage of device construction, clinical applications, socioeconomic implications, and future directions. Master the pathophysiology and rationale of treatment with discussions of basic science in addition to clinically-relevant information and current clinical practice guidelines. Apply the expertise of the world’s most prominent leaders in mechanical circulatory support. |
| cardiac gene therapy companies: Suggestions to Medical Authors and A.M.A. Style Book American Medical Association, 1919 |
| cardiac gene therapy companies: Stress Echocardiography Eugenio Picano, 2015-10-06 This sixth edition is enriched by over 300 figures, 150 tables and a video-companion collecting more than 100 cases also presented in the format of short movies and teaching cartoons. This extensively revised and enlarged edition of this long-seller documents the very significant advances made since the fifth (2009) edition and is entirely written by Eugenio Picano, a pioneer in the field sharing his lifetime experience with the help of an international panel of 50 contributors from 22 countries representing some of the best available knowledge and expertise in their respective field. In a societal and economic climate of increasing pressure for appropriate, justified and optimized imaging, stress echocardiography offers the great advantages of being radiation-free, relatively low cost, and with a staggering versatility: we can get more (information) with less (cost and risk). For a long time, the scope and application of stress echo remained focused on coronary artery disease. In the last ten years, it has exploded in its breadth and variety of applications. From a black-and-white, one-fits-all approach (wall motion by 2D-echo in the patient with known or suspected coronary artery disease) now we have moved on to a omnivorous, next-generation laboratory employing a variety of technologies (from M-Mode to 2D and pulsed, continuous, color and tissue Doppler, to lung ultrasound and real time 3D echo, 2D speckle tracking and myocardial contrast echo) on patients covering the entire spectrum of severity (from elite athletes to patients with end-stage heart failure) and ages (from children with congenital heart disease to the elderly with low-flow, low-gradient aortic stenosis). |
| cardiac gene therapy companies: Aging and the Heart José Marín-García, 2007-12-07 In this book, the genetic and molecular basis of cardiovascular aging is examined in detail and a comprehensive assessment given of the bioenergetics changes occurring in human and animal models of cardiac aging. Both current diagnostic and future therapeutic modalities are presented, giving this book a dual-pronged approach. Cardiac aging, like aging in general, is a complex process involving numerous cellular and molecular changes. This book sheds new light on the phenomenon. |
| cardiac gene therapy companies: Breath James Nestor, 2020-05-26 A New York Times Bestseller A Washington Post Notable Nonfiction Book of 2020 Named a Best Book of 2020 by NPR “A fascinating scientific, cultural, spiritual and evolutionary history of the way humans breathe—and how we’ve all been doing it wrong for a long, long time.” —Elizabeth Gilbert, author of Big Magic and Eat Pray Love No matter what you eat, how much you exercise, how skinny or young or wise you are, none of it matters if you’re not breathing properly. There is nothing more essential to our health and well-being than breathing: take air in, let it out, repeat twenty-five thousand times a day. Yet, as a species, humans have lost the ability to breathe correctly, with grave consequences. Journalist James Nestor travels the world to figure out what went wrong and how to fix it. The answers aren’t found in pulmonology labs, as we might expect, but in the muddy digs of ancient burial sites, secret Soviet facilities, New Jersey choir schools, and the smoggy streets of São Paulo. Nestor tracks down men and women exploring the hidden science behind ancient breathing practices like Pranayama, Sudarshan Kriya, and Tummo and teams up with pulmonary tinkerers to scientifically test long-held beliefs about how we breathe. Modern research is showing us that making even slight adjustments to the way we inhale and exhale can jump-start athletic performance; rejuvenate internal organs; halt snoring, asthma, and autoimmune disease; and even straighten scoliotic spines. None of this should be possible, and yet it is. Drawing on thousands of years of medical texts and recent cutting-edge studies in pulmonology, psychology, biochemistry, and human physiology, Breath turns the conventional wisdom of what we thought we knew about our most basic biological function on its head. You will never breathe the same again. |
| cardiac gene therapy companies: Post-Genomic Cardiology José Marín-García, 2014-05-09 In this second edition of Post-Genomic Cardiology, developing and new technologies such as translational genomics, next generation sequencing (NGS), bioinformatics, and systems biology in molecular cardiology are assessed in light of their therapeutic potential. As new methods of mutation screening emerge, both for the genome and for the epigenome, comprehensive understanding of the many mutations that underlie cardiovascular diseases and adverse drug reactions is within our reach. This book, written by respected cardiologist José Marín-García, features discussion on the Hap-Map: the largest international effort to date aiming to define the differences between our individual genomes. This unique reference further reviews and investigates genome sequences from our evolutionary relatives that could help us decipher the signals of genes, and offers a comprehensive and critical evaluation of regulatory elements from the complicated network of the background DNA. - Offers updated discussion of cutting-edge molecular techniques including new genomic sequencing / NGS / Hap-Map / bioinformatics / systems biology approaches - Analyzes mitochondria dynamics and their role in cardiac dysfunction, up-to-date analysis of cardio-protection, and cardio-metabolic syndrome - Presents recent translational studies, gene therapy, transplantation of stem cells, and pharmacological treatments in CVDs |
| cardiac gene therapy companies: Cardiac Anesthesia Fawzy G. Estafanous, Paul G. Barash, J. G. Reves, 2001 The thoroughly updated Second Edition of this highly acclaimed text provides a concise yet comprehensive reference on the clinical and scientific principles of cardiovascular and thoracic anesthesia. The foremost authorities in cardiac anesthesia cover topics particular to this specialized field, such as extracorporeal circulation, transesophageal echocardiography, the physiology and pharmacology of anticoagulation, cardiac catheterization, invasive cardiology, and congenital heart disease. Ideal for residents, fellows, and practicing anesthesiologists, this important text provides comprehensive, practical guidance for all aspects of cardiac anesthesia. |
Heart - Wikipedia
In humans, the heart is approximately the size of a closed fist and is located between the lungs, in the middle compartment of the chest, called the mediastinum. [4]
Heart disease - Symptoms and causes - Mayo Clinic
Aug 13, 2024 · Heart disease describes a range of conditions that affect the heart. Heart disease includes: Blood vessel disease, such as coronary artery disease. Irregular heartbeats, called …
Cardiovascular Disease: Types, Causes & Symptoms - Cleveland Clinic
Cardiovascular disease includes heart or blood vessel issues, including: Narrowing of the blood vessels in your heart, other organs or throughout your body. Heart and blood vessel problems …
Cardiovascular system: Function, organs, conditions, and more
May 22, 2025 · Common conditions that can affect the cardiovascular system include coronary artery disease, heart attack, high blood pressure, and stroke. This article explores the …
CARDIAC Definition & Meaning - Merriam-Webster
The meaning of CARDIAC is of, relating to, situated near, or acting on the heart. How to use cardiac in a sentence.
Cardiovascular (Heart) Diseases: Types and Treatments - WebMD
Oct 29, 2024 · Cardiovascular disease is a group of conditions that affect your heart and blood vessels. It's sometimes also called heart disease. Conditions that affect your heart and blood …
Heart | Structure, Function, Diagram, Anatomy, & Facts | Britannica
5 days ago · heart, organ that serves as a pump to circulate the blood. It may be a straight tube, as in spiders and annelid worms, or a somewhat more elaborate structure with one or more …
CARDIAC | English meaning - Cambridge Dictionary
CARDIAC definition: 1. of the heart or heart disease: 2. a cardiac arrest (= a heart attack): 3. of the heart or…. Learn more.
Cardiovascular System Anatomy and Physiology - Nurseslabs
Apr 29, 2024 · Journey to the heart of our being with the cardiovascular system study guide. Aspiring nurses, chart the pulsating rivers of life as you discover the anatomy and dynamics of …
Cardiac | definition of cardiac by Medical dictionary
1. pertaining to the heart. 2. pertaining to the ostium cardiacum. cardiac arrest sudden and often unexpected stoppage of effective heart action.
Heart - Wikipedia
In humans, the heart is approximately the size of a closed fist and is located between the lungs, in the middle compartment of the chest, called the mediastinum. [4]
Heart disease - Symptoms and causes - Mayo Clinic
Aug 13, 2024 · Heart disease describes a range of conditions that affect the heart. Heart disease includes: Blood vessel disease, such as coronary artery disease. Irregular heartbeats, called …
Cardiovascular Disease: Types, Causes & Symptoms - Cleveland Clinic
Cardiovascular disease includes heart or blood vessel issues, including: Narrowing of the blood vessels in your heart, other organs or throughout your body. Heart and blood vessel problems …
Cardiovascular system: Function, organs, conditions, and more
May 22, 2025 · Common conditions that can affect the cardiovascular system include coronary artery disease, heart attack, high blood pressure, and stroke. This article explores the …
CARDIAC Definition & Meaning - Merriam-Webster
The meaning of CARDIAC is of, relating to, situated near, or acting on the heart. How to use cardiac in a sentence.
Cardiovascular (Heart) Diseases: Types and Treatments - WebMD
Oct 29, 2024 · Cardiovascular disease is a group of conditions that affect your heart and blood vessels. It's sometimes also called heart disease. Conditions that affect your heart and blood …
Heart | Structure, Function, Diagram, Anatomy, & Facts | Britannica
5 days ago · heart, organ that serves as a pump to circulate the blood. It may be a straight tube, as in spiders and annelid worms, or a somewhat more elaborate structure with one or more …
CARDIAC | English meaning - Cambridge Dictionary
CARDIAC definition: 1. of the heart or heart disease: 2. a cardiac arrest (= a heart attack): 3. of the heart or…. Learn more.
Cardiovascular System Anatomy and Physiology - Nurseslabs
Apr 29, 2024 · Journey to the heart of our being with the cardiovascular system study guide. Aspiring nurses, chart the pulsating rivers of life as you discover the anatomy and dynamics of …
Cardiac | definition of cardiac by Medical dictionary
1. pertaining to the heart. 2. pertaining to the ostium cardiacum. cardiac arrest sudden and often unexpected stoppage of effective heart action.
